Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)

被引:36
作者
Rosenberg, J. E. [1 ]
Milowsky, M. [2 ]
Ramamurthy, C. [3 ]
Mar, N. [4 ]
Mckay, R. R. [5 ]
Friedlander, T. [6 ]
Ferrario, C. [7 ]
Bracarda, S. [8 ]
George, S. [9 ]
Moon, H. [10 ]
Geynisman, D. [11 ]
Petrylak, D. P. [12 ]
Borchiellini, D. [13 ]
Burgess, E. F. [14 ]
Rey, J. P. Maroto [15 ]
Carret, A-S. [16 ]
Yu, Y. [17 ]
Guseva, M. V. [18 ]
Moreno, B. Homet [19 ]
O'Donnell, P. H. [20 ]
机构
[1] MSKCC Mem Sloan Kettering Canc Ctr, Med Dept, New York, NY USA
[2] Univ North Carolina Chapel Hill, Med Dept, Chapel Hill, NC USA
[3] Univ Texas Hlth Sci Ctr San Antonio, Mays Canc Ctr, Hematol, San Antonio, TX USA
[4] Univ Calif Irvine, UCI Hlth, Hematol Oncol, Orange, CA USA
[5] Univ Calif San Diego, Med Oncol, La Jolla, CA USA
[6] UCSF Univ Calif San Francisco, Oncol, San Francisco, CA USA
[7] Jewish Gen Hosp, Oncol, Montreal, PQ, Canada
[8] Azienda Osped Santa Maria, Med Translat Oncol Unit, Terni, Italy
[9] Roswell Pk Comprehens Canc Ctr, Med Dept, Buffalo, NY USA
[10] Kaiser Permanente Riverside Med Ctr, Oncol Dept, Riverside, CA USA
[11] Fox Chase Canc Ctr, Med Oncol Dept, Main Campus, Philadelphia, PA USA
[12] Yale Univ, Med Oncol Dept, Sch Med, New Heaven, CT USA
[13] Ctr Antoine Lacassagne, Oncol, Nice, France
[14] Levine Canc Inst, Dept Med Oncol, Charlotte, NC USA
[15] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[16] Seagen Inc, Clin Dev, Bothell, WA USA
[17] Seagen Inc, Biostat, Bothell, WA USA
[18] Astellas Pharma USA, Oncol, Global Medica Affairs, Northbrook, IL USA
[19] Merck & Co Inc, Clin Res, Rahway, NJ USA
[20] Univ Chicago, Hematol & Oncol, Chicago, IL USA
关键词
D O I
10.1016/j.annonc.2022.08.079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
LBA73
引用
收藏
页码:S1441 / S1441
页数:1
相关论文
empty
未找到相关数据